10月15日，西维斯健康盘中上涨3.02%，报90.195美元/股，成交额3.68亿美元。
消息面上，美国司法部表示，西维斯健康同意支付3.15亿美元和解金，以解决非法调配违规阿片类药物处方并向联邦政府提交虚假索赔的指控。
从近期背景看，市场同时关注公司基本面修复与估值调整。多家机构近阶段仍维持买入或增持立场，最新目标价下调后仍在112美元附近，明显高于现价；公司下一次财报将于11月4日披露，市场预期每股收益1.62美元。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.